← Human Trials & Peer-Reviewed Studies
Effect of somatostatin in advanced gastric cancer after D2 radical gastrectomy
Plain-language guide to PMID 25356053 (2014): single-blind randomized controlled trial study of Somatostatin.
Key Facts
- PMID
- 25356053
- Journal
- World journal of gastroenterology
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Song W et al. (8 authors)
- DOI
- 10.3748/wjg.v20.i40.14927
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Somatostatin.
To study the effect of somatostatin in patients with advanced gastric cancer who received D2 lymphadenectomy and vagina vasorum dissection.
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
Using a prospective, single-blind, placebo-controlled design, patients with advanced gastric cancer were randomized into a study group (n = 61) and a control group (n = 59).
Patients in the study group were given somatostatin for 5-7 d starting 6 h after the operation, and patients in the control group were given normal saline.
How the Study Was Run
The researchers set it up as a randomized, single-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Somatostatin and who got the comparison, which limits bias.
Only one side, usually the participants, was kept unaware of whether Somatostatin was given.
Some participants received a placebo instead of Somatostatin, giving a reference point.
Preoperative and nonoperative complications in the perioperative period, as well as different types of postoperative drainage in the two groups were compared.
What Was Measured
PubMed files the paper under topics including Antineoplastic Agents, Chemotherapy, Adjuvant, China, Drainage, Gastrectomy, Lymph Node Excision and Neoplasm Staging.
The authors tagged it with the keywords Advanced gastric cancer, Complications and Somatostatin.
What This Means in Plain Language
The paper is a randomized, single-blind and placebo-controlled study of Somatostatin.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2014 (World journal of gastroenterology), a journal based in United States.
More context: the Somatostatin compound page, all human trials.
Our Notes on the Compound
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.